A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage i non-small cell lung cancer (SWOG-0720, NCT00792701)

Cancer

Volumn 120, Issue 15, 2014, Pages 2343-2351

  Bepler, Gerold ^a   Zinner, Ralph G ^b   Moon, James ^c   Calhoun, Royce ^d   Kernstine, Kemp ^e   Williams, Charles C ^f   Mack, Philip C ^d   Oliveira, Vasco ^a   Zheng, Zhong ^f   Stella, Philip J ^g   Redman, Mary W ^b   Gandara, David R ^d  

^a KARMANOS CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c SWOG STATISTICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g Michigan Cancer Research Consortium   (United States)

Author keywords

adjuvant therapy; ERCC1 (excision repair cross complementing group 1); lung cancer; personalized medicine; RRM1 (ribonucleotide reductase M1)

Indexed keywords

ALANINE AMINOTRANSFERASE; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; RRM1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ALGORITHM; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DISEASE FREE SURVIVAL; ERCC1 GENE; FAINTNESS; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL STATUS; GENE EXPRESSION ASSAY; HEARING IMPAIRMENT; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPONATREMIA; IMAGE ANALYSIS; IMMUNOFLUORESCENCE TEST; KIDNEY FAILURE; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM LYMPH NODE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RRM1 GENE; SIDE EFFECT; SINUS BRADYCARDIA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; ADJUVANT CHEMOTHERAPY; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DECISION MAKING; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PERSONALIZED MEDICINE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84904723291     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28714     Document Type: Article

References (32)

1. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J,; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350: 351-360.
2. Winton TL, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin versus observation in resected non-small-cell lung cancer. N Engl J Med. 2005; 352: 2589-2597.
3. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small-cell lung cancer: report of the Cancer and Leukemia Group B protocol 9633 [abstract]. Proc Am Soc Clin Oncol. 2004; 23: Page. Abstract 7019.
4. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008; 26: 5043-5051.
5. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E,. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest. 1994; 94: 703-708.
6. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998; 16: 309-316.
7. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002; 8: 2286-2291.
8. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355: 983-991.
9. Reynolds C, Obasaju C, Schell MJ, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009; 27: 5808-5815.
10. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA,. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 2004; 64: 3761-3766.
11. Bergman A, Eijk P, van Haperen V, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as a major determinant. Cancer Res. 2005; 65: 9510-9516.
12. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006; 24: 4731-4737.
13. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006; 17: 1818-1825.
14. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol. 2004; 22: 1878-1885.
15. Simon GR, Sharma S, Cantor A, Smith P, Bepler G,. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005; 127: 978-983.
16. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G,. The DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007; 356: 800-808.
17. Camp RL, Chung GG, Rimm DL,. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002; 8: 1323-1327.
18. Bepler G, Williams C, Schell MJ, et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013; 31: 2404-2412.
19. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ. 1995; 311: 899-909.
20. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst. 2003; 95: 1453-1461.
21. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004; 26: 173-182.
22. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006; 7: 719-727.
23. Pignon JP, Tribodet H, Scagliotti GV, et al. LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26: 3552-3559.
24. Waller D, Fairlamb DJ, Gower N, et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer. Preliminary results in the surgical setting. Lung Cancer. 2003; 41: 54.
25. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P,; International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009; 4: 792-801.
26. Bepler G, Olaussen KA, Vataire AL, et al. ERCC1 and RRM1 in the International Adjuvant Lung Trial by automated quantitative in situ analysis. Am J Pathol. 2011; 179: 69-78.
27. Friboulet L, Olaussen KA, Pignon JP, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013; 369: 1101-1110.
28. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ,. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res. 2009; 69: 6831-6838.
29. Ma D, Baruch D, Shu Y, et al. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnol. 2012; 12: 88.
30. Vaezi A, Bepler G, Bhagwat N, et al. CCTα is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in lung and head and neck squamous cell carcinomas. Cancer. In press.
31. Reed E,. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998; 24: 331-344.
32. Chen Z, Zhou J, Zhang Y, Bepler G,. Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide. Biochem Biophys Res Commun. 2011; 413: 383-388.